Lisinopril cough treatment
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that losartan, valsartan, and telmisartan are potential alternatives to lisinopril for hypertensive patients experiencing ACE inhibitor-induced cough.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Lisinopril-Induced Cough: Treatment and Alternatives
Introduction to Lisinopril-Induced Cough
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is commonly prescribed for hypertension and heart failure. However, a significant side effect associated with lisinopril is a persistent dry cough. This adverse effect can be troublesome for patients, leading to discontinuation of the medication. Understanding the incidence, mechanisms, and alternative treatments for lisinopril-induced cough is crucial for effective patient management.
Incidence and Mechanism of Lisinopril-Induced Cough
The incidence of cough in patients taking lisinopril is notably high. Studies have shown that the occurrence of dry cough can range from 60% to 97% in patients with a history of ACE inhibitor-induced cough . The mechanism behind this side effect is believed to be related to the accumulation of bradykinin and substance P, which are not adequately broken down due to the inhibition of ACE, leading to irritation of the respiratory tract.
Gender Differences in Lisinopril-Induced Cough
Research indicates a higher prevalence of lisinopril-induced cough in women compared to men. In a study, women reported cough three times more often than men when treated with lisinopril (12.6% vs. 4.4%). This gender difference highlights the need for careful monitoring and consideration of alternative treatments, especially in female patients.
Alternative Treatments: Angiotensin II Receptor Antagonists
Angiotensin II receptor antagonists (ARBs) such as losartan, valsartan, and telmisartan have been identified as effective alternatives to ACE inhibitors, with a significantly lower incidence of cough. Multiple studies have demonstrated that ARBs are associated with a much lower rate of cough compared to lisinopril .
- Losartan: In several studies, losartan showed a significantly lower incidence of cough (18%-36.7%) compared to lisinopril (68.9%-97%) . This makes losartan a viable alternative for patients who develop a cough with lisinopril.
- Valsartan: Similarly, valsartan was associated with a lower incidence of cough (19.5%) compared to lisinopril (68.9%).
- Telmisartan: Telmisartan also demonstrated a lower incidence of cough (15.6%) compared to lisinopril (60%) and was comparable to placebo.
Clinical Implications and Recommendations
For patients experiencing lisinopril-induced cough, switching to an ARB such as losartan, valsartan, or telmisartan can significantly reduce the incidence of this side effect while maintaining effective blood pressure control. These alternatives are well-tolerated and do not compromise the therapeutic efficacy required for managing hypertension.
Conclusion
Lisinopril-induced cough is a common and bothersome side effect that can lead to discontinuation of therapy. ARBs such as losartan, valsartan, and telmisartan offer effective alternatives with a significantly lower risk of cough. Clinicians should consider these alternatives, especially for patients who develop a cough with lisinopril, to ensure continued management of hypertension without compromising patient comfort and adherence to treatment.
Sources and full results
Most relevant research papers on this topic
